PPARG and type 2 diabetes mellitus: It has been shown that combined treatment with a drug used to treat type 2 diabetes (pioglitazone) and apha-galactosylceramide induces lipid synthesis via PPARγ activation and significantly enhances iNKT cell-mediated antitumor immune response [131].